ReviewAnnual review of medicine2020
Atherosclerosis: Making a U Turn.
Review in Annual review of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Platelets impair the resolution of inflammation in atherosclerotic plaques in insulin-resistant mice after lipid lowering.JCI insight · 2025Article
- Recent insights into the pathophysiology and implications for surgery in atherosclerosis.Journal of cardiothoracic surgery · 2025Review
- HDLR-SR-BI Expression and Cholesterol Uptake are Regulated via Indoleamine-2,3-dioxygenase 1 in Macrophages under Inflammation.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- The association between basilar artery wall thickness and posterior circulation ischemic stroke: insights from high-resolution vascular wall imaging in subclinical atherosclerosis.Frontiers in neurology · 2025Article
- Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies.Journal of clinical medicine · 2024Article
- Allograft Model of Aortic Arch Segment Grafting to Abdominal Aorta Through End-to-Side Anastomosis in Mice.Journal of cardiovascular translational research · 2024Article
- Article
- β-carotene accelerates the resolution of atherosclerosis in mice.bioRxiv : the preprint server for biology · 2024Article
- Preclinical and translational models for delirium: Recommendations for future research from the NIDUS delirium network.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside.International journal of molecular sciences · 2023Review
- Characteristics and evaluation of atherosclerotic plaques: an overview of state-of-the-art techniques.Frontiers in neurology · 2023Review
- Circular RNAs in Cardiovascular Diseases: Regulation and Therapeutic Applications.Research (Washington, D.C.) · 2023Review
- Diagnostics of atherosclerosis: Overview of the existing methods.Frontiers in cardiovascular medicine · 2023Review
- Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release.International journal of molecular sciences · 2022Article
- Long-Term Preoperative Atorvastatin or Rosuvastatin Use in Adult Patients before CABG Does Not Increase Incidence of Postoperative Acute Kidney Injury: A Propensity Score-Matched Analysis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Article
- Review
- Mechanisms of vascular smooth muscle cell investment and phenotypic diversification in vascular diseases.Biochemical Society transactions · 2021Review
- Silencing Myeloid Netrin-1 Induces Inflammation Resolution and Plaque Regression.Circulation research · 2021Article
- Effects of withdrawing an atherogenic diet on the atherosclerotic plaque in rabbits.Experimental and therapeutic medicine · 2021Article
- Effect of nondipper hypertension on coronary artery disease progression in patients with chronic coronary syndromeTurkish journal of medical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The development of potent cholesterol-reducing medications in the last decade of the twentieth century has altered the approach to prevention and treatment of cardiovascular disease (CVD). Initial experience with statins, and more recently with the addition of PCSK9 inhibitors, has proven that human CVD, like that in animal models, can be halted and regressed. Available clinical data show that the lower the achieved level of low-density lipoprotein cholesterol, the greater the regression of disease. Investigative studies are now aimed to understand those factors that both accelerate and impede this healing process. Some of these are likely to be modifiable, and the future of atherosclerotic CVD treatment is likely to be early screening, use of measures to repair atherosclerotic arteries, and prevention of most CVD events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.